#EAN2018

#EAN2018 – Slowly Evolving Lesions Monitored Using MTR Scans May Be Marker of SPMS Progression

An MRI technique known as magnetization transfer ratio (MTR) correlated closely with theĀ progression ofĀ slowly evolving lesions (SELs) ā€” aĀ specific type of multiple sclerosis lesion ā€” in patients with secondary progressive MS (SPMS). According to the researchers, monitoring changes in SELs ā€” which indicate demyelination and loss of nerve fibers ā€”…

#EAN2018 – MavencladĀ Greatly Reduces Risk of RRMS Relapse, Analysis Finds

New retrospective analysis of the Phase 3 CLARITY study (NCT00213135)Ā shows that treatment with MavencladĀ (cladribine tablets) improved annualized relapse rate and magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of their age. Moreover, the effectiveness of Mavenclad was comparable to five standard therapies…

#EAN2018 – Levels ofĀ Neurofilament Light Chain Can Predict Disease Progression in RRMS, Study Shows

Levels ofĀ neurofilament light chain are a reliable predictor of disease worsening and progression in relapsing-remitting MS (RRMS) patients, a new study shows. Moreover, treatment withĀ GilenyaĀ (fingolimod), marketed by Novartis, can reduce the levels ofĀ NfL for up to 10 years. These findings were shared recently in the presentation ā€œ…

#EAN2018 ā€“ Ocrevus Lowers Relapse Rates Over Long Term and Better Than Rebif Does, Data Show

Long-term treatment with Ocrevus (ocrelizumab) Ā ā€” as well as switching from Rebif (interferon beta-1a) to Ocrevus ā€” leads to a significant and sustained reduction in disease activity in relapsing forms of multiple sclerosis (MS). TheseĀ previouslyĀ reportedĀ findingsĀ are further supported by the latest results drawn from pooled data…